<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://dermfield.com/articles/ccl21-icam1-niche-accelerates-ot-i-t-cell-hits-against-b16-melanoma-6373e67a</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T20:25:02.722Z</news:publication_date>
      <news:title>CCL21-ICAM1 niche accelerates OT-I T-cell hits against B16 melanoma</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/recognizing-skin-conditions-in-children-with-darker-skin-tones-7d0cf540</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T19:55:02.705Z</news:publication_date>
      <news:title>Recognizing Skin Conditions in Children With Darker Skin Tones</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/atopic-dermitis-leaves-marks-on-education-and-career-paths-study-finds-0c903f53</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T19:55:02.705Z</news:publication_date>
      <news:title>Atopic Dermitis Leaves Marks on Education and Career Paths, Study Finds</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/international-panel-reaches-consensus-on-tapering-psoriasis-biologics-2157b816</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T19:55:02.705Z</news:publication_date>
      <news:title>International Panel Reaches Consensus on Tapering Psoriasis Biologics</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/sun-pharma-s-unloxcyt-earns-nccn-category-2a-status-for-advanced-skin-cancer-79646ef5</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T19:25:02.676Z</news:publication_date>
      <news:title>Sun Pharma&apos;s Unloxcyt Earns NCCN Category 2A Status for Advanced Skin Cancer</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/oral-psoriasis-therapy-icotyde-sustains-response-at-two-years-1fa1923d</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T18:25:02.608Z</news:publication_date>
      <news:title>Oral Psoriasis Therapy ICOTYDE Sustains Response at Two Years</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/jak-inhibitors-for-alopecia-areata-counseling-and-agent-choice-667d7f08</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T17:55:02.578Z</news:publication_date>
      <news:title>JAK Inhibitors for Alopecia Areata: Counseling and Agent Choice</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/aad-and-hs-foundation-release-first-joint-hidradenitis-suppurativa-guidelines-20ca39c6</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T17:55:02.578Z</news:publication_date>
      <news:title>AAD and HS Foundation Release First Joint Hidradenitis Suppurativa Guidelines</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/jak-inhibitors-for-alopecia-areata-selectivity-meets-pivotal-trial-efficacy-58332251</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T17:25:02.555Z</news:publication_date>
      <news:title>JAK Inhibitors for Alopecia Areata: Selectivity Meets Pivotal Trial Efficacy</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/dupixent-lawsuit-filed-after-mycosis-fungoides-diagnosis-eb842f5d</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T17:20:02.552Z</news:publication_date>
      <news:title>Dupixent Lawsuit Filed After Mycosis Fungoides Diagnosis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/skin-longevity-demands-evidence-not-marketing-hype-644be6ed</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T16:50:02.516Z</news:publication_date>
      <news:title>Skin Longevity Demands Evidence, Not Marketing Hype</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://dermfield.com/articles/flare-program-targets-sun-protection-in-melanoma-risk-children-74e03177</loc>
    <news:news>
      <news:publication>
        <news:name>Derm Field</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-20T16:50:02.516Z</news:publication_date>
      <news:title>FLARE Program Targets Sun Protection in Melanoma-Risk Children</news:title>
    </news:news>
  </url>
</urlset>
